Associate Medical Director/Medical Director

Role / ResponsibilitiesJounce Therapeutics is very excited about INNATE, our Phase 1/2 clinical study of JTX-8064, the first tumor-associated macrophage candidate developed from Jounces Translational Science Platform. We are seeking a motivated Medical Director to lead all clinical activities related to the program including contributing to development and execution of clinical development strategy, study oversight, and leadership of the clinical sub team for the JTX-8064 program. For a Board-certified medical oncologist without industry experience, this position offers the opportunity to make meaningful strategic contributions while learning all aspects of oncology drug development in a fast paced and translationally focused biotech environment. JTX-8064 is a humanized IgG4 monoclonal antibody designed to specifically bind to the macrophage receptor LILRB2, acting as a Macrophage Checkpoint Inhibitor. INNATE is the Phase 1/2 clinical study of JTX-8064 as a monotherapy and in combination with pimivalimab, Jounces PD-1 inhibitor, in patients with advanced solid tumors. The study progressed quickly through dose escalation and is now enrolling in Phase 2 tumor specific expansion cohorts designed to demonstrate proof of concept. Jounce announced recently that two of 7 combination expansion cohorts met the prespecified response criteria to continue enrollment beyond the first stage of a Simon 2-stage design. Patients with PD-(L)1 inhibitor resistant tumors represent a large and growing unmet medical need. INNATE will also assess potential predictive biomarkers to guide future development, aligning with Jounces philosophy of developing the right immunotherapies for the right patients. Responsibilities: Design innovative and feasible clinical trials in collaboration with program leadership, translational research, and clinical team members; Author clinical trial documents including but not limited to protocols, charters, IND reports, process documents, meeting presentations, publications, and clinical sections of regulatory documents such as INDs, briefing books, clinical study reports, investigator brochures, annual reports and updates, and clinical sections of regulatory submissions to support product approvals; Partner with Data Management for case report form (CRF) design, instructions for unique CRFs, and Data Quality Plan; Interact frequently with investigators to share new scientific and clinical data and maintain enthusiasm and engagement to optimize clinical trial enrollment; Participate actively as the clinical development expert in study implementation, study oversight and study medical monitoring; Conduct regular review, analysis, and interpretation of study results; Participate in tracking/analysis of any potential safety events across trials for JTX-8064; Serve as primary point of contact for clinical study inquiries from site staff, CROs and site monitors regarding the study protocol, modifications to informed consent, and scientific or medically related questions; Present at internal and external meetings (e.g., portfolio reviews, clinical advisory boards, investigator meetings, pre-study site selection visits and site initiation visits, Study Coordinator and CRA training, and internal and external medical/scientific meetings); Maintain awareness and keep program team informed of internal and external developments that may impact the investigational agent Clinical Development Plan, including attendance at major scientific conferences, participation in competitive intelligence activities, and periodic literature review; Maintain current knowledge of the external environment to ensure scientific innovations are considered and/or incorporated into clinical trial development strategy; Participate in development of the long-range strategic plans for the assigned program(s); and Lead clinical sub-team meetings. Qualifications The candidate must have a Medical Degree. Board certified in internal medicine (or pediatrics) and medical oncology or hematology (or pediatric oncology) would be preferable; 2+ years of industry/related experience in cancer related research, drug development and clinical development, preferably in immuno-oncology is preferred. Industry experience will be waived for Board certified medical oncologists; Good knowledge of clinical research and experience across Phase I III drug development projects preferred; Experience working effectively on cross-functional teams (matrix organization) and with external vendors including Contract Research Organizations; Familiarity with clinical trial design and experience authoring clinical trial protocols (Phase I or II); Strong Scientific/ Translational experience and experience with biomarker strategies preferred; Experience in the analysis and interpretation of clinical data and assessment of clinical relevance; Comprehensive understanding of safety profiles and risks; Well-versed in medical aspects of GCP, ICH, FDA, EMA, and other relevant guidelines; and Ability to work independently and to organize priorities and deliverables Strong verbal and written skills. StatementDiversity and Inclusion Statement Jounce strives to create a workplace that reflects the diversity of cancer patients, and where all feel included and valued because of their differences. Actively including people who add to our culture and enhance our values leads to better decisions and outcomes for those we serve patients, all patients. Beyond our walls, our focus is on addressing inequities in opportunities for STEM education, careers opportunities in Biotech, and access to cancer care. Equal Opportunity Employer Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S. Company SummaryJounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounces highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounces internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounces most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Created: 2025-11-15